UNSPSC 51422335: Dexamethasone beloxil

This classification denotes a therapeutic glucocorticoid and antiemetic agent C29H35FO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V9T15U399I, chemically known as (11.beta.,16.alpha.)-9-fluoro-3,17-dihydroxy-16-methyl-21(phenylmethoxy)-pregna-1,4-diene-3,20-dione, but more generally known as dexamethasone beloxil, which bears US NIH Compound Identifier 656778. Most nations, for tariff and trade purposes, schedule dexamethasone beloxil under HS 29372200 and SITC 54153.

As of Q4 2014, DEXAMETHASONE BELOXIL remains US FDA's Preferred Term for this commodity. Dexamethasone beloxil bears US NLM identifiers UMLS ID C2699608 and NCI Concept Code C77415. SMILES: C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COCC5CCCCC5)O)C)O)F)C.

UNSPSC 51422335 Dexamethasone beloxil, a Commodity code, nominally addresses a specific pharmaceutical product, but recent state and local procurement activity under this code shows a significant scope mismatch. The most recent opportunities tagged to this code involve naloxone procurement and direct-to-manufacturer prescription program design — neither of which aligns with the code's stated pharmaceutical name. Seminole County, Florida issued an IFB on June 30, 2026 (response deadline July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually through community health procurement, with quarterly deliveries and fixed-fee pricing. The Texas Health and Human Services Commission posted an RFI on April 3, 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program — a market-research phase designed to inform future RFP strategy rather than a competitive procurement with binding terms. The code shows little relevant recent activity aligned to its nominal pharmaceutical scope; state and local purchasing offices appear to be applying the dexamethasone code to broader pharmaceutical procurement and pharmacy program work that does not match the Commodity-level product specificity the code represents.

Geographic spread is limited to Florida and Texas in the recent-opportunities record. Both solicitations originate from county health agencies and state HHS commissions rather than from a broad issuing-body mix. Without additional opportunities demonstrating consistent use of this code for its intended pharmaceutical product, the signal for active dexamethasone procurement at the state and local level is weak. Vendors targeting this code should verify that their product eligibility and pricing align with how individual jurisdictions tag pharmaceutical purchases, as the current activity suggests either code-tagging inconsistency or a need to clarify whether this Commodity code is in active use for its core pharmaceutical scope or has been repurposed for broader health procurement categories.